Synthetic inhibitor leads of human tropomyosin receptor kinase A (hTrkA)
Journal article published in 2020 by
Govindan Subramanian 
,
Rajendran Vairagoundar,
Scott J. Bowen,
Nicole Roush,
Theresa Zachary,
Christopher Javens,
Tracey Williams,
Ann Janssen,
Andrea Gonzales
,
Rajendran Vairagoundar,
Scott J. Bowen,
Nicole Roush,
Theresa Zachary,
Christopher Javens,
Tracey Williams,
Ann Janssen,
Andrea Gonzales
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
New hTrkA kinase domain type 2 inhibitors and mixed type 1/type 2 inhibitor leads disclosed here offers a differential starting point to investigate the disease pathophysiology.